Abstract
Introduction 53
The pathophysiology of schizophrenia is understood to involve dysfunction of the 54 dopaminergic (Carlsson, 1988) , serotonergic (Meltzer and Massey, 2011) , glutamatergic 55 (Coyle, 2006) and GABA-ergic (Gonzalez-Burgos and Lewis, 2008) neurotransmitter 56 systems. The diverse psychopathology of schizophrenia cannot be explained by dysfunction 57 of neurotransmitter systems when considered in isolation (Keshavan et al., 2011) . Adenosine, 58 a homeostatic neuromodulator, is an emerging candidate neurobiological substrate with 59 effects on multiple neurotransmitter pathways (Boison, 2008; Cunha and Cunha, 2001 ). In 60 addition, adenosine plays an important role in early brain development and regulation of 61 brain immune responses (Cunha and Cunha, 2001) , and thereby could also contribute to the 62 neurodevelopmental deviations implicated in schizophrenia (Lara et al., 2006) . 63
Adenosine deaminase (ADA) is a purine-inactivating endoenzyme that irreversibly 64 deaminates adenosine to inosine (Yegutkin, 2008) , leading to its final degradation to uric 65 acid. Like adenosine, ADA too is ubiquitously found in the human body (Franco et al., 1997) 66 and hence implicated in diverse physiological functions. Thus, serum ADA level has been 67 suggested as an important peripheral biomarker of adenosine signaling in neuropsychiatric 68 disorders (Elgün et al., 1999; Herken et al., 2007; Stubbs et al., 1982) especially in 69 schizophrenia, given that a hypoadenosinergic state has been linked to its pathogenesis (Lara 70 et al., 2006) . 71
In support of the above, Dutra et al. (Dutra et al., 2010 ) demonstrated lower frequency of 72 occurrence of an ADA variant with decreased enzymatic activity (G/A genotype) among 73 patients with schizophrenia, suggesting increased levels of ADA and reduced levels of 74 ambient adenosine. Another study reported significantly higher serum ADA in patients with 75 schizophrenia on antipsychotic monotherapy (more so with atypical antipsychotic), when 76 compared to healthy control subjects (Brunstein et al., 2007) , but found no correlation with 77 clinical psychopathology. However, Ghaleiha et al. (Ghaleiha et al., 2011) , reported that in 78 patients with chronic schizophrenia, antipsychotic therapy (particularly with clozapine) was 79 associated with an increase in serum ADA and symptomatic improvement. Therefore, it is 80 unclear whether the increased serum ADA reported in the above studies was the consequence 81 of treatment with antipsychotics or a marker of the disorder per se. 82 Therefore, we examined whether serum ADA levels were significantly different in patients 83
with schizophrenia who have never been exposed to antipsychotic medications in comparison 84 to matched healthy comparison subjects. In accordance with the proposed adenosine theory 85 of schizophrenia pathophysiology, we hypothesized that the serum ADA will be significantly 86 higher in patients with schizophrenia. We also aimed at exploring the hitherto unreported 87 relationship between serum ADA and symptom severity scores. 88
Materials and Methods

89
The study was carried out at the National Institute of Mental Health and Neurosciences 90 (NIMHANS), Bangalore, India, with due approval from the Institute Ethics Committee thus 91 conforming to the ethical standards laid down in the 1964 Declaration of Helsinki. Written 92 informed consent was obtained from all the participants prior to enrolment into the study. 93 not peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. Positive and negative symptoms were rated using the Scale for Assessment of Positive 113 symptoms (SAPS) (Andreasen, 1983) and Scale for Assessment of Negative symptoms 114 (SANS) (Andreasen, 1982) respectively by one rater (S.K.) for all subjects after undergoing 115 adequate training and establishment of inter-rater reliability. None of the patients had history 116 of exposure to neuroleptic medications. 117
The healthy comparison subjects were recruited from the community through word-of-mouth. 118
They were screened to exclude past history of Axis I psychiatric disorders, personal history 119 of psychoactive medication use and family history of schizophrenia spectrum disorders in 120 first-degree relatives using a study-specific proforma. 121
All participants were screened to exclude history of significant head injury, neurological 122 disorders, medical conditions including acute infections, autoimmune disorders, endocrine 123 disorders, specific sleep disorders, and substance abuse including caffeine (daily intake of 124 caffeine-containing beverages and food substances exceeding 300mg/day). All were free of 125 any drugs known to affect immune or endocrine function. All participants underwent clinical 126 screening to rule out any unstable medical conditions. The participants were instructed to 127 avoid food and caffeine for at least 3 hours before the evening blood sample, following which 128 they had their dinner; overnight fasting was ensured before drawing the morning blood 129 sample. The above precautionary measures were adopted to avoid any confounding effects, 130
including that of food and caffeine on the measured ADA levels. 131
Measurement of ADA
132
Blood samples were collected from participants before and after their sleep as there was no 133 available evidence from the literature regarding the most appropriate time to collect serum for 134 ADA assay. The first sample was collected around 7p.m. (before dinner and before sleep) 135 not peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprint (which was . http://dx.doi.org/10.1101/070748 doi: bioRxiv preprint first posted online Aug. 21, 2016; similar to a previous schizophrenia study (Brunstein et al., 2007 ) and the second sample 136 around 7a.m. the following morning (after sleep and before breakfast) similar to earlier 137 studies in major depression (Elgün et al., 1999; Herken et al., 2007 were analyzed in duplicate and the intra-assay variability was less than 10%. Assays were 150 conducted at the Department of Neurochemistry under the supervision of S.S. The trained 151 neurochemist who carried out the assays was blinded to the study group status of the blood 152 samples. 153
Genotyping of ADA polymorphism 154
The ADA 22G>A polymorphism (rs73598374) was genotyped using allele-specific 155 polymerase-chain reaction under the supervision of M.P and S.J. Genotyping was done for 32 156 (HS=16; SZ=16) out of the 35 subjects, all of whom were found to have the G/G genotype. 157
Therefore, any further examination of the relationship between the ADA rs73598374 158 genotypes and serum ADA levels and the differences between patients with schizophrenia 159 and healthy comparison subjects was not possible in our limited sample. 160
Statistical analysis
161
Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, Inc.) and 162
Statistical Toolbox of MATLAB 2012b (Mathworks, USA). D'Agostino and Pearson 163 omnibus test and visual inspection of histogram plot was used to determine the normality of 164 data distribution. As ADA levels of both groups did not follow normal distribution, statistical 165 analyses were done on their log transformed values which followed a normal distribution. All 166 other values, except age, followed normal distribution. Mann-Whitney U-test was used to 167 test the group difference in age. Between-group comparisons for ADA levels of the 7p.m. 168
(ADAeven) and of the 7a.m. (ADAmorn) samples as well as their difference (ADAdiff(even-morn)), 169 were done using the Student's t-test, after conducting a permutation-based two-way ANOVA 170 that found no group vs time interactions (Table 1) . Comparisons between ADAeven and 171
ADAmorn levels within each group were carried out using paired t-test. The significance level 172 for these tests was set at p<0.05. Pearson's test was used to test correlations of ADA levels 173 (ADAeven, ADAmorn and ADAdiff(even-morn)) with duration of illness, positive symptom scores 174 and negative symptom scores within the schizophrenia group. Spearman rank order 175 correlation test was used for the within-group correlations between ADA levels and age. All 176 the SAPS and SANS sub-scores (including their total scores) were included in the correlation 177 analysis, and thus 11 correlations were made for each ADA level (ADAeven, ADAmorn and 178 not peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
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ADAdiff(even-morn)). To exclude accidental significance associated with multiple correlations, a 179 threshold value of 0.735 was set for the absolute correlation co-efficients (α=0.05; n=11) 180 using G*power 3.1 software (Faul et al., 2009 (Faul et al., , 2007 in order to obtain a statistical power 181 greater than 80% (Sabri et al., 1997) . All tests were assessed using two-tailed p values. 182
Results
183
In the two-way ANOVA, significant main effects were noted only for the group factor, while 184 there were no time effects or group x time interactions ( ADAdiff(even-morn) and avolition-apathy sub-score of SANS ( 
Discussion
209
The present study found significantly higher serum ADA levels at two different time points 210 (7p.m. on day1 and 7a.m. on day2) in patients with recent-onset schizophrenia who had never 211 been exposed to neuroleptic medications, in comparison to matched healthy comparison 212 subjects. The study also provides evidence for a link between ADA levels and 213 psychopathology in patients with schizophrenia. (Fig. 1B) . This might reflect the within-group differences in severity of the various 236 psychopathological dimensions. Interestingly we found a significant positive correlation 237 between ADAdiff(even-morn) and auditory hallucinations and a trend towards an inverse 238 correlation between ADAdiff(even-morn) and avolition-apathy. The positive correlation between 239
higher ADAeven (relative to ADAmorn) and auditory hallucinations ( Fig. 2A and 2B ADAeven) and avolition-apathy ( Fig. 2A and 2C It is pertinent to mention at this juncture that adenosine and other nucleosides are transported 260 across the blood-brain barrier via a saturable, carrier mediated mechanism (Kalaria and 261
Harik, 1988). The increased ADA activity in the periphery, as seen in patients with drug 262 naïve schizophrenia, may result in reduction of the circulatory levels of adenosine. This may 263 decrease the transport across the blood-brain barrier (BBB) leading to a hypoadenosinergic 264 not peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
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It may be argued that the higher ADA found in our patient sample may be a compensatory 269 phenomenon secondary to a state-dependent increase in brain adenosine levels during the 270 psychotic state (Cunha and Cunha, 2001; Hirayama et al., 2011; Reddy et al., 1992) . 271
However, this argument fails to explain the overall ADA rise noted even among patients with 272 the negative symptom of avolition-apathy. As our patient group comprised of subjects with 273 heterogeneous symptom dimensions ( Fig. 2A) , it is unlikely that the higher ADA could have 274 exclusively resulted from higher state-dependent adenosine levels. Thus, the increased ADA 275 levels detected in our sample of patients with schizophrenia may be considered as a 276 peripheral marker of a hypoadenosinergic state that characterizes the disorder. Similarly, 277 medication induced elevation of serum ADA reported by Ghaleiha et al. (2011) in patients 278 with schizophrenia could be compensatory to an improvement in adenosinergic tone 279 associated with successful treatment. It has to be stated that these are indeed preliminary 280 hypotheses generated from the results of the study, which need to be tested in future studies 281 with larger sample sizes. 282
Adenosine has been shown to serve a regulatory function in the immune system of brain 283 (Haskó et al., 2005) . Though general immunological disorders were ruled out in all our 284 subjects through careful history and routine clinical hematological and biochemical screening 285 investigations, we did not carry out screening blood investigations to rule out autoimmune 286 conditions. Although remote associations between acute psychotic states, encephalitis and 287 NMDA auto-antibodies have been reported (Deakin et al., 2014), schizophrenia has not been 288 conclusively shown to be an autoimmune disorder (Coutinho et al., 2014) . Therefore, it is 289 unlikely that the raised ADA levels observed in our sample of patients with schizophrenia 290 could be secondary to an autoimmune state. 291
A potential limitation of the study is the fact that only protein levels of ADA in serum were 292 measured, while enzymatic activity of ADA was not assayed. While measuring the enzyme 293 activity offers greater correlation with physiological response, the practical difficulties in 294 handling the samples prompted us to measure the ADA protein levels. In our earlier pilot 295 studies, we observed a gradual decrease in the ADA enzyme activity when the serum samples 296 were stored at 4 o C or when subjected to two freeze-thaw cycles. However, as expected, the 297 ADA protein content remained unaltered upon storage/ freeze thawing. The present study 298 involved the recruitment of drug naïve subjects with schizophrenia over a substantial time 299
period. The samples were collected as and when the subjects were recruited and the serum 300 separated and stored. To avoid inter-assay variation, all the samples were analyzed at the 301 same time. In order to avoid any bias in the results due to varying lengths of sample storage, 302 it was considered appropriate to measure the protein content. Moreover, ADA also has 303 significant non-enzymatic actions (protein-protein interactions) with respect to desensitizing 304 and enhancing functionality of adenosine receptors (Ciruela et al., 2010; Gracia et al., 2008) . 305
Therefore, a protein level assessment may be a better indicator of the full range of ADA 306 activity in comparison to enzyme activity. 307 not peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
Finally, in our limited sample of neuroleptic-naïve patients with recent-onset schizophrenia 308 and matched healthy comparison subjects, all the genotyped subjects (HS=16; SZ=16) were 309 found to have G/G genotype of the ADA 22G>A polymorphism (rs73598374); none of the 310 subjects had the G/A genotype that is associated with lower ADA activity (Bachmann et al., 311 2012; Battistuzzi et al., 1981) . Larger samples of schizophrenia and healthy subjects may be 312 needed to observe between-group differences, if any, of the G/G and G/A genotypes as 313 reported in one previous study (Dutra et al., 2010) . Nevertheless, since all our subjects were 314 homogeneous with respect to the ADA 22G>A functional polymorphic variation, it may be 315 inferred that our observation of higher serum ADA levels in patients with schizophrenia is 316 unlikely to be confounded by genotypic variation between the study samples. 317
Conclusion
318
To the best of our knowledge, this is the first report of elevated serum ADA levels at two 319 time points in neuroleptic-naïve patients with recent-onset schizophrenia. Further, the study 320 also provides preliminary evidence for a link between ADA levels at different time points 321 with positive and negative symptoms of schizophrenia. These findings may be considered 322 strong evidences in support of the adenosine hypothesis of schizophrenia. In the background 323 of previous reports suggesting a possible genetic basis for the elevated ADA activity in 324 schizophrenia and the observation of alteration of ADA levels with successful treatment, the 325 potential utility of serum ADA levels as a biomarker or endophenotype of schizophrenia 326 should be researched in future studies. 327
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